mat2a protein Search Results


mat2a knockdown  (TargetMol)
93
TargetMol mat2a knockdown
Mat2a Knockdown, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mat2a knockdown/product/TargetMol
Average 93 stars, based on 1 article reviews
mat2a knockdown - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
mat2a protein  (Feto Maternal and GenetYX Center)
90
Feto Maternal and GenetYX Center mat2a protein
Mat2a Protein, supplied by Feto Maternal and GenetYX Center, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mat2a protein/product/Feto Maternal and GenetYX Center
Average 90 stars, based on 1 article reviews
mat2a protein - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mat2a protein  (Pharmaron Inc)
90
Pharmaron Inc mat2a protein
Reversing CD8A + T cell deficiency by methionine metabolism intervention enhancing immunotherapy response in MTAP-deleted osteosarcoma (A) Flowchart depicting methionine restriction diet combined with immune checkpoint therapy. (B and C) In vivo orthotopic tibia models of DuNN shMtap in C3H mice, depicting tumor growth curves (mean ± SD) and tumor weights at experimental endpoints, treated by methionine restriction diet combined with immune checkpoint therapy. ND n = 8; ICT n = 8; MR n = 8; Combined n = 8. Statistical analyses were performed using two-tailed Student’s t tests. (D) Metabolomics of the intestines in DuNN shMtap tumor-bearing C3H mice revealed downregulation of methionine-related metabolites following dietary methionine restriction. (E) Pathological characteristics and immunohistochemistry (CD8A) of tumor tissues from DuNN shMtap in C3H mice, treated by methionine restriction diet combined with immune checkpoint therapy. Arrows indicate T cells. Scale bar, 100 μm (F) Flowchart depicting <t>MAT2A</t> inhibition combined with immune checkpoint therapy. (G and H) In vivo orthotopic tibia models of DuNN shMtap in C3H mice, depicting tumor growth curves (mean ± SD) and survival curve at experimental endpoints, treated by MAT2A inhibition combined with immune checkpoint therapy. ND n = 6; ICT n = 6; MR n = 6; Combined n = 6. Statistical analyses were performed using two-tailed Student’s t tests. (I) Pathological characteristics and immunohistochemistry (CD8A, CD4, and FOXP3) of tumor tissues from DuNN shMtap in C3H mice, treated by MAT2A inhibition combined with immune checkpoint therapy. Arrows indicate T cells. Scale bar, 100 μm.
Mat2a Protein, supplied by Pharmaron Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mat2a protein/product/Pharmaron Inc
Average 90 stars, based on 1 article reviews
mat2a protein - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mat2a, his-tag recombinant  (BPS Bioscience)
93
BPS Bioscience mat2a, his-tag recombinant
Reversing CD8A + T cell deficiency by methionine metabolism intervention enhancing immunotherapy response in MTAP-deleted osteosarcoma (A) Flowchart depicting methionine restriction diet combined with immune checkpoint therapy. (B and C) In vivo orthotopic tibia models of DuNN shMtap in C3H mice, depicting tumor growth curves (mean ± SD) and tumor weights at experimental endpoints, treated by methionine restriction diet combined with immune checkpoint therapy. ND n = 8; ICT n = 8; MR n = 8; Combined n = 8. Statistical analyses were performed using two-tailed Student’s t tests. (D) Metabolomics of the intestines in DuNN shMtap tumor-bearing C3H mice revealed downregulation of methionine-related metabolites following dietary methionine restriction. (E) Pathological characteristics and immunohistochemistry (CD8A) of tumor tissues from DuNN shMtap in C3H mice, treated by methionine restriction diet combined with immune checkpoint therapy. Arrows indicate T cells. Scale bar, 100 μm (F) Flowchart depicting <t>MAT2A</t> inhibition combined with immune checkpoint therapy. (G and H) In vivo orthotopic tibia models of DuNN shMtap in C3H mice, depicting tumor growth curves (mean ± SD) and survival curve at experimental endpoints, treated by MAT2A inhibition combined with immune checkpoint therapy. ND n = 6; ICT n = 6; MR n = 6; Combined n = 6. Statistical analyses were performed using two-tailed Student’s t tests. (I) Pathological characteristics and immunohistochemistry (CD8A, CD4, and FOXP3) of tumor tissues from DuNN shMtap in C3H mice, treated by MAT2A inhibition combined with immune checkpoint therapy. Arrows indicate T cells. Scale bar, 100 μm.
Mat2a, His Tag Recombinant, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mat2a, his-tag recombinant/product/BPS Bioscience
Average 93 stars, based on 1 article reviews
mat2a, his-tag recombinant - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
mat2a protein, human, recombinant  (TargetMol)
N/A
   Buy from Supplier
human mat2a recombinant protein liquid  (Innovative Research Inc)
N/A
Human MAT2A Recombinant Protein Liquid from Innovative Research has been recombinantly produced in E. coli. This is a Liquid protein buffered in 10 mM Tris, pH 8.0, 0.1% Triton X-100, 0.002% NaN3 with a purity
   Buy from Supplier
mat2a nm 145569 mouse recombinant protein  (OriGene)
N/A
Purified recombinant protein of Mouse methionine adenosyltransferase II alpha Mat2a with C terminal MYC DDK tag expressed in HEK293T cells 20ug
   Buy from Supplier
recombinant human mat2a protein  (Novus Biologicals)
N/A
The Recombinant Human MAT2A Protein from Novus Biologicals is derived from E coli The Recombinant Human MAT2A Protein has been validated for the following applications SDS Page
   Buy from Supplier
human mat2a recombinant protein  (Boster Bio)
N/A
Human MAT2A Recombinant Protein expressed in E. coli with His-tag. Sequence domain: 1-395aa. Application(s): SDS-PAGE.
   Buy from Supplier
mat2a 1 395 his tag human protein  (OriGene)
N/A
MAT2A 1 395 His tag human recombinant protein 0 5 mg
   Buy from Supplier
mat2a protein  (Biosynth Carbosynth)
N/A
1-395 amino acids: MGSSHHHHHH SSGLVPRGSH MNGQLNGFHE AFIEEGTFLF TSESVGEGHP DKICDQISDA VLDAHLQQDP DAKVACETVA KTGMILLAGE ITSRAAVDYQ KVVREAVKHI GYDDSSKGFD YKTCNVLVAL EQQSPDIAQG VHLDRNEEDI GAGDQGLMFG YATDETEECM PLTIVLAHKL NAKLAELRRN GTLPWLRPDS KTQVTVQYMQ DRGAVLPIRV HTIVISVQHD EEVCLDEMRD ALKEKVIKAV VPAKYLDEDT IYHLQPSGRF VIGGPQGDAG LTGRKIIVDT YGGWGAHGGG AFSGKDYTKV DRSAAYAARW
   Buy from Supplier

Image Search Results


Reversing CD8A + T cell deficiency by methionine metabolism intervention enhancing immunotherapy response in MTAP-deleted osteosarcoma (A) Flowchart depicting methionine restriction diet combined with immune checkpoint therapy. (B and C) In vivo orthotopic tibia models of DuNN shMtap in C3H mice, depicting tumor growth curves (mean ± SD) and tumor weights at experimental endpoints, treated by methionine restriction diet combined with immune checkpoint therapy. ND n = 8; ICT n = 8; MR n = 8; Combined n = 8. Statistical analyses were performed using two-tailed Student’s t tests. (D) Metabolomics of the intestines in DuNN shMtap tumor-bearing C3H mice revealed downregulation of methionine-related metabolites following dietary methionine restriction. (E) Pathological characteristics and immunohistochemistry (CD8A) of tumor tissues from DuNN shMtap in C3H mice, treated by methionine restriction diet combined with immune checkpoint therapy. Arrows indicate T cells. Scale bar, 100 μm (F) Flowchart depicting MAT2A inhibition combined with immune checkpoint therapy. (G and H) In vivo orthotopic tibia models of DuNN shMtap in C3H mice, depicting tumor growth curves (mean ± SD) and survival curve at experimental endpoints, treated by MAT2A inhibition combined with immune checkpoint therapy. ND n = 6; ICT n = 6; MR n = 6; Combined n = 6. Statistical analyses were performed using two-tailed Student’s t tests. (I) Pathological characteristics and immunohistochemistry (CD8A, CD4, and FOXP3) of tumor tissues from DuNN shMtap in C3H mice, treated by MAT2A inhibition combined with immune checkpoint therapy. Arrows indicate T cells. Scale bar, 100 μm.

Journal: Cell Reports Medicine

Article Title: Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma

doi: 10.1016/j.xcrm.2025.101977

Figure Lengend Snippet: Reversing CD8A + T cell deficiency by methionine metabolism intervention enhancing immunotherapy response in MTAP-deleted osteosarcoma (A) Flowchart depicting methionine restriction diet combined with immune checkpoint therapy. (B and C) In vivo orthotopic tibia models of DuNN shMtap in C3H mice, depicting tumor growth curves (mean ± SD) and tumor weights at experimental endpoints, treated by methionine restriction diet combined with immune checkpoint therapy. ND n = 8; ICT n = 8; MR n = 8; Combined n = 8. Statistical analyses were performed using two-tailed Student’s t tests. (D) Metabolomics of the intestines in DuNN shMtap tumor-bearing C3H mice revealed downregulation of methionine-related metabolites following dietary methionine restriction. (E) Pathological characteristics and immunohistochemistry (CD8A) of tumor tissues from DuNN shMtap in C3H mice, treated by methionine restriction diet combined with immune checkpoint therapy. Arrows indicate T cells. Scale bar, 100 μm (F) Flowchart depicting MAT2A inhibition combined with immune checkpoint therapy. (G and H) In vivo orthotopic tibia models of DuNN shMtap in C3H mice, depicting tumor growth curves (mean ± SD) and survival curve at experimental endpoints, treated by MAT2A inhibition combined with immune checkpoint therapy. ND n = 6; ICT n = 6; MR n = 6; Combined n = 6. Statistical analyses were performed using two-tailed Student’s t tests. (I) Pathological characteristics and immunohistochemistry (CD8A, CD4, and FOXP3) of tumor tissues from DuNN shMtap in C3H mice, treated by MAT2A inhibition combined with immune checkpoint therapy. Arrows indicate T cells. Scale bar, 100 μm.

Article Snippet: MAT2A protein , Pharmaron Inc. , This study.

Techniques: In Vivo, Two Tailed Test, Immunohistochemistry, Inhibition

MAT2A inhibition triggering IKZF1-mediated PD-L1 expression in MTAP-deleted osteosarcoma (A, B, and C) Integrated analysis of transcription factors associated with PD-L1 expression in SGH-OS and TARGET-OS and genes upregulated by treating with MAT2A inhibitor rather than immune checkpoint therapy. Spearman correlation tests were performed, and data with p values < 0.05 were considered statistically significant. (D and E) Protein expression of MAT2A and PD-L1 in MTAP-deleted OS cells (143B) treated with MAT2A inhibitor PF-9366, and protein expression of IKZF1, MAT2A, and PD-L1 in 143B cells co-treated with siIKZF1, assessed by western blotting. (F) IKZF1 RNA expression in wild-type (WT) ( n = 36) and MTAP-deleted (DEL) ( n = 14) cases in SGH-OS cohort. Statistical analyses were performed using two-tailed Student’s t tests. (G) Transcriptomic pathway analysis of cells by treating with PF-9366, using GSEA analysis ( p value < 0.05) on Hallmark gene sets. ES refers to enrichment score, and NES refers to normalized enrichment score. (H and I) Survival curve of TARGET-OS and TCGA-SARC related with IKZF1 expression. Statistical significance was calculated using the log rank test. (J) Summary schematic illustrating the mechanism of methionine intervention enhancing immune checkpoint therapy in MTAP-deleted osteosarcoma (MTAP-del OS).

Journal: Cell Reports Medicine

Article Title: Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma

doi: 10.1016/j.xcrm.2025.101977

Figure Lengend Snippet: MAT2A inhibition triggering IKZF1-mediated PD-L1 expression in MTAP-deleted osteosarcoma (A, B, and C) Integrated analysis of transcription factors associated with PD-L1 expression in SGH-OS and TARGET-OS and genes upregulated by treating with MAT2A inhibitor rather than immune checkpoint therapy. Spearman correlation tests were performed, and data with p values < 0.05 were considered statistically significant. (D and E) Protein expression of MAT2A and PD-L1 in MTAP-deleted OS cells (143B) treated with MAT2A inhibitor PF-9366, and protein expression of IKZF1, MAT2A, and PD-L1 in 143B cells co-treated with siIKZF1, assessed by western blotting. (F) IKZF1 RNA expression in wild-type (WT) ( n = 36) and MTAP-deleted (DEL) ( n = 14) cases in SGH-OS cohort. Statistical analyses were performed using two-tailed Student’s t tests. (G) Transcriptomic pathway analysis of cells by treating with PF-9366, using GSEA analysis ( p value < 0.05) on Hallmark gene sets. ES refers to enrichment score, and NES refers to normalized enrichment score. (H and I) Survival curve of TARGET-OS and TCGA-SARC related with IKZF1 expression. Statistical significance was calculated using the log rank test. (J) Summary schematic illustrating the mechanism of methionine intervention enhancing immune checkpoint therapy in MTAP-deleted osteosarcoma (MTAP-del OS).

Article Snippet: MAT2A protein , Pharmaron Inc. , This study.

Techniques: Inhibition, Expressing, Western Blot, RNA Expression, Two Tailed Test

Journal: Cell Reports Medicine

Article Title: Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma

doi: 10.1016/j.xcrm.2025.101977

Figure Lengend Snippet:

Article Snippet: MAT2A protein , Pharmaron Inc. , This study.

Techniques: Control, Recombinant, Saline, Red Blood Cell Lysis, Lysis, Staining, Screening Assay, Transfection, Plasmid Preparation, In Vitro, CCK-8 Assay, Cell Isolation, Gene Expression, Sequencing, Methylation, In Vivo, Software, Microscopy, Refractive Index, Mass Spectrometry